Evidence map›Paper›PMID 29080741›Full record

ArticleMethods (San Diego, Calif.)2018

Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.

Sanders Oh, John A Kessler

Abstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025
    Review
  9. Review
  10. Article
  11. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.Tissue engineering and regenerative medicine · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. mRNA vaccines for COVID-19: what, why and how.International journal of biological sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sanders OhDepartment of Neurology, Northwestern University, Chicago, IL, USA. Electronic address: sanders.oh@northwestern.edu.
John A KesslerDepartment of Neurology, Northwestern University, Chicago, IL, USA.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARDEHALI, HOSSEIN · 1987 to 2021
$24.0M
Medical Scientist Training ProgramT32GM144295 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ALAN R HAUSER · 2022 to 2026
$9.1M
Research Education Program for Trainees in NeurologyR25NS070695 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KESSLER, JOHN A, SIMUNI, TANYA · 2010 to 2023
$1.4M
Training for a New Interdisciplinary Research Workforce in Regenerative MedicineT90DA022881 · NIDA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KESSLER, JOHN A · 2006 to 2009
$1.1M
NIDA NIH HHS T90 DA022881NIGMS NIH HHS T32 GM008152NIGMS NIH HHS T32 GM144295NINDS NIH HHS R25 NS070695
6 · The paper itself

Abstract

Proteins are drivers of cell functions and are targets of many therapies. Exogenous protein expression techniques, therefore, have been essential for research and medicine. The most common method for exogenous protein expression relies on DNA-based viral or non-viral vectors. However, DNA-based vectors have the potential to integrate into the host genome and cause permanent mutations. RNA-based vectors solve this shortcoming. In particular, synthetic modified mRNA provides non-viral, integration-free, zero-footprint method for expressing proteins. Modified mRNA can direct cell fate specification and cellular reprogramming faster and more efficiently than other methods. Furthermore, when simultaneously express multiple different proteins, mRNA vectors allow for greater flexibility and control over stoichiometric ratios, dose titrations, and complete silencing of expressions. Additionally, modified mRNAs have been shown to be viable and safe as therapeutic agents for gene therapy and vaccine, providing an alternative approach to address diseases. Despite these advantages, technical challenge, mRNA instability, and host immunogenicity have caused significant barriers to widespread use of this technology. The comprehensive method presented here addresses all of these shortcomings. This stepwise protocol describes every step necessary for the synthesis of modified mRNA from any coding DNA sequence of interest. The meticulously detailed protocol enables the users to make alterations to each component of modified mRNA for even more significant customization, allowing the researchers to apply this technology to a wide range of uses. This non-cytotoxic synthetic modified mRNA can be used for protein expression, regulation of cell reprogramming or differentiation, and drug delivery.

Indexed as

Genetic TherapyInduced Pluripotent Stem CellsCell DifferentiationCellular ReprogrammingDNAFibroblastsGenetic VectorsHumansRNA, MessengerTransfectionDNARNA, MessengerMessenger RNAModified mRNAmRNA protocolmRNA reprogrammingmRNA synthesismRNA transfectionReprogramming factorsSynthetic mRNA

Identifiers

PMID29080741
PMCPMC5807177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.